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Although epidemiological cutoff values (ECVs) have been established for Candida spp. and the triazoles, they are based onMIC
data from a single laboratory. We have established ECVs for eight Candida species and fluconazole, posaconazole, and voricona-
zole based on wild-type (WT) MIC distributions for isolates of C. albicans (n 11,241 isolates), C. glabrata (7,538), C. parapsi-
losis (6,023), C. tropicalis (3,748), C. krusei (1,073), C. lusitaniae (574), C. guilliermondii (373), and C. dubliniensis (162). The
24-h CLSI broth microdilutionMICs were collated frommultiple laboratories (in Canada, Brazil, Europe, Mexico, Peru, and the
United States). The ECVs for distributions originating from>6 laboratories, which included>95% of the modeledWT popula-
tion, for fluconazole, posaconazole, and voriconazole were, respectively, 0.5, 0.06 and 0.03g/ml for C. albicans, 0.5, 0.25, and
0.03g/ml for C. dubliniensis, 8, 1, and 0.25g/ml for C. glabrata, 8, 0.5, and 0.12g/ml for C. guilliermondii, 32, 0.5, and 0.25
g/ml for C. krusei, 1, 0.06, and 0.06 g/ml for C. lusitaniae, 1, 0.25, and 0.03 g/ml for C. parapsilosis, and 1, 0.12, and
0.06 g/ml for C. tropicalis. The low number of MICs (<100) for other less prevalent species (C. famata, C. kefyr, C. orthopsilo-
sis, C. rugosa) precluded ECV definition, but their MIC distributions are documented. Evaluation of our ECVs for some species/
agent combinations using published individual MICs for 136 isolates (harboring mutations in or upregulation of ERG11,MDR1,
CDR1, or CDR2) and 64WT isolates indicated that our ECVsmay be useful in distinguishingWT from non-WT isolates.
Severe candidal infections are seenworldwide among immuno-compromised hosts and nonimmunocompromised patients.
Irrespective of the species, these infections are associated with
high mortality and morbidity rates (1, 2). In addition to the dif-
ferent amphotericin B formulations, the triazoles are recom-
mended as primary (fluconazole and voriconazole) and prophy-
lactic (fluconazole and posaconazole) treatments for invasive
infections caused by Candida spp. (3, 4). The azoles block the
pathway of ergosterol biosynthesis by inhibiting the 14--lanos-
terol demethylase enzyme. The wide use of fluconazole and other
triazoles has led to in vitro resistance among Candida and other
fungal isolates to fluconazole and, to a lesser extent, the newer
triazoles, voriconazole and posaconazole (5). Various molecular
mechanisms are associated with in vitro resistance to triazoles
among Candida spp., such as (i) modifications in the quality or
quantity of the target enzyme, reduced access of the drug to the
target, mutations in the ERG genes participating in ergosterol bio-
synthesis, or a combination of these mechanisms, and (ii) active
efflux of azole out of the cell through the activation of multidrug
efflux transporters encoded by the MDR and CDR genes (6–12).
The Clinical and Laboratory Standards Institute (CLSI) Subcom-
mittee on Antifungal Susceptibility Tests has adjusted the break-
points (BPs) for fluconazole and voriconazole to be species spe-
cific (13). A recent study defined triazole epidemiological cutoff
values (ECVs) (12) based on data from a single laboratory for the
triazoles and several species of Candida; however, BPs are not
available for posaconazole and any fungal species or for the less
prevalent species and fluconazole and voriconazole. The ECV, de-
fined as the highest susceptibility endpoint of the wild-type (WT)
population MIC, has been shown to detect the emergence of in
vitro resistance or to separate WT isolates (without known mech-
anisms of resistance) from non-WT isolates (with mechanisms of
resistance and reduced susceptibilities to the agent being evalu-
ated) (12, 14–16). The data from multiple laboratories used to
define ECVs in the present study should bemore representative of
the susceptibilities of these species to the triazoles evaluated.
The purpose of this study was (i) to define the wild-type sus-
ceptibility endpoint distributions of fluconazole, posaconazole,
and voriconazole for 5 common and 3 less commonCandida spp.
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originating from 6 laboratories and (ii) to propose ECVs for
these 3 triazoles using the 24-h CLSI broth microdilution method
(17). We aggregated MICs obtained in 15 independent laborato-
ries (29 to 11,241, species and agent dependent). MIC distribu-
tions for other less prevalent Candida species (C. famata, C. kefyr,
C. orthopsilosis,C. rugosa) also are documented. In addition, since
our isolates have not been assessed for mechanisms of resistance,
we evaluated our ECVs using available studies where MICs for
individual isolates, determined using broth microdilution meth-
ods, and the presence or absence ofmechanisms of resistancewere
reported for some of the species included in the present study
(6–8, 10, 18–26).
MATERIALS AND METHODS
Isolates.Each isolate originated fromaunique clinical specimen from1of
18 independent laboratories. In the present study, the MICs of the three
triazoles used for ECV definition were obtained at the following medical
centers: VCU Medical Center, Richmond, VA; Instituto de Medicina
Tropical Alexander Von Humboldt, Universidad Peruana Cayetano
Heredia, Lima, Peru; Unidad de Microbiologia Experimental, Hospital
Universitario La Fe, Valencia, Spain; University of Texas Health Science
Center, San Antonio, TX; The University of Alberta, Edmonton, Alberta,
Canada; Universidad Nacional Autónoma de México, Mexico; The Inns-
bruck Medical University, Innsbruck, Austria; Centers for Disease Con-
trol and Prevention, Atlanta, GA; Hospital Universitario de Valme, Sev-
ille, Spain; Department of Medical Microbiology and Infectious Diseases,
Canisius-Wilhelmina Hospital, Nijmegen, Netherlands; The Adolfo Lutz
Institute, São Paulo City, Brazil; University of Texas Health Science Cen-
ter, Houston, TX; Hospital General Universitario Gregorio Marañón,
Faculty of Medicine, Universidad Complutense, Madrid, Spain; Univer-
sity of Iowa, Iowa City, IA; Mycology Department, Adolfo Lutz Institute,
São Paulo City, Brazil; Institut National de Santé Publique du Québec,
Laboratoire de Santé Publique du Québec, Quebec, Canada; Adolfo Lutz
Institute, Araçatuba City, Brazil; Facultat deMedicina, IISPV,URV, Reus,
Spain. These laboratories were coded 1 to 20 (for several studies), but
because some laboratories were excluded from the study or did not pro-
vide triazole MIC data for some species, we used data from the remaining
15 laboratories. Species were identified and stored at each medical center
using standard and molecular methodologies (27), and isolates were not
evaluated for azole resistance mechanisms.
We aggregated the available 24-h CLSI MIC data of each agent for
11,241 C. albicans, 162 C. dubliniensis, 7,538 C. glabrata, 373 C. guillier-
mondii, 1,073 C. krusei, 574 C. lusitaniae, 6,023 C. parapsilosis, and 3,748
C. tropicalis isolates originating from 6 to 15 different laboratories and for
four other less prevalent species (49 C. famata, 36 C. kefyr, 68 C. orthop-
silosis, and 76 C. rugosa isolates) from 3 to 9 different laboratories (Tables
1 to 3). One or both quality control (QC) isolates (C. parapsilosis ATCC
22019 and C. krusei ATCC 6258) were used by the participating laborato-
ries (13, 17).
In addition, we included triazole MIC distributions from previously
published studies (5 species, 73 to 200 isolates, 20 to 64 WTMICs and 53
to 136 non-WT MICs [agent dependent]), all tested for the presence
(non-WT) or absence (WT) of either intrinsic or acquired azole resistance
mechanisms (e.g., substitutions and missense mutations in or upregula-
tion of ERG11,MDR1, CDR1, and CDR2), in order to assess the ability of
the various fluconazole, posaconazole, and voriconazole ECVs to discrim-
inate non-WT from WT strains of Candida spp. at the molecular level
(6–8, 10, 18–26).
Antifungal susceptibility testing. The MICs were obtained at each
center by following the CLSIM27-A3 broth microdilutionmethod (stan-
dard RPMI 1640 broth [0.2% dextrose], final inoculum concentrations
that ranged from 0.5 103 to 5 103 CFU/ml, and 24 h of incubation);
MICs were the lowest drug concentrations that produced50% growth
inhibition compared to the growth control (17).MIC data for the twoQC
reference strains, utilized during the years of testing in each center, were
obtained each time that a set of isolates was tested following the CLSI
M27-A3 broth microdilution method (13, 17). The majority of MIC
ranges (98 to 100%) for the two QC strains were within the CLSI estab-
lished reference range in each laboratory that had data included in the
analyses; a certain degree of interlaboratory modal variability (mostly
2-fold dilution) was observed.
Definitions. The ECV (also known as the wild-type cutoff, or COWT)
definition and the definitions of the two populations (WT and non-WT
MIC populations or isolates) that will be discussed have been provided
above (12, 14–16, 28). Briefly, a non-WT organism shows reduced sus-
ceptibility to the agent being evaluated compared to the WT (without
resistant mechanisms) population, but it may or may not respond to
treatment with the drug being evaluated. ECVs are calculated by taking
into account the MIC distribution, the modal MIC of each distribution,
and the inherent variability of the test (usually within one doubling dilu-
tion) and should encompass95% of isolates (28).
Data analysis. As previously described (28–32), the MIC distribution
of each species obtained in each coded laboratory (numbered 1 to 20) was
listed in an Excel spreadsheet and screened for (i) grossly skewed distri-
butions that precluded statistical fitting (distributions that had a modal
MIC [most frequent value] at the lowest or highest concentration tested
and/or which were bimodal in the presumptive wild-type distribution),
TABLE 1 Pooled MIC distributions of fluconazole for 12 Candida species
Species
No. of
labsa
No. of
isolates
No. of isolates for which the MIC (g/ml) wasb:
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
C. albicans 9c 5,265 254 1,729 1,647 855 370 137 91 59 48 37 26 12
C. dubliniensis 7c 162 18 54 55 21 5 1 2 3 2 1
C. glabrata 14 7,538 29 78 189 474 2,065 2,676 773 343 322 441 148
C. guilliermondii 11c 373 4 7 20 68 160 87 12 6 4 3 2
C. krusei 11 1,073 1 1 2 9 23 165 554 227 83 8
C. lusitaniae 10c 574 1 76 181 199 64 12 4 8 8 15 6
C. parapsilosis 15 6,023 8 233 2,021 2,479 655 288 136 82 74 23 21 3
C. tropicalis 14 3,748 24 558 1,464 963 446 146 61 35 26 8 14 3
C. famata 9 49 9 16 12 7 2 3
C. kefyr 7 36 5 16 12 1 1 1
C. orthopsilosis 4 68 3 14 29 13 6 2 1
C. rugosa 9 76 1 3 14 24 23 5 4 2
a Number of laboratories contributing data to each MIC distribution.
b MICs determined at 24 h as described in the CLSI M27-A3 reference method (17). The modal MIC (most frequent value) for each distribution is underlined.
c Data from the other 1 to 4 labs were not used due to abnormal MIC distributions (the mode and lowest concentration tested were the same).
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(ii) distribution size (data from3 laboratories and the total pooled dis-
tribution had 100 isolates), and (iii) unusual modal variation (modes
that were2-fold dilutions from the others). Skewed distributions were
removed from each pooled distribution of each species/agent used for the
analysis (28, 31). The resulting screened and pooled MIC distributions
were used to calculate the ECVs by the statistical method where the mod-
eled population is based on fitting a normal distribution at the lower end
of the MIC range, calculating the mean and standard deviation of that
normal distribution, and using those parameters to calculate theMIC that
captures at least 95%, 97.5%, and 99% of the modeled WT population
(28).
RESULTS AND DISCUSSION
The ultimate goal of susceptibility testing is to predict with some
reliability the clinical outcome when an infected patient is treated
with the specific agent evaluated. The endpoint that categorizes an
MIC as susceptible or resistant is the BP (14–16). However, in the
fungal world, there are many species and agent combinations for
which BPs have not been proposed. The reason for that is the lack
of sufficient data correlating clinical outcomes and in vitro results
used to establish BPs. That is the case for posaconazole and Can-
dida spp., the other triazoles for some of the less prevalent Can-
dida species, and for C. glabrata versus voriconazole (13). Al-
though the ECV is not a BP, ECVs serve as an early indication of
emerging changes in the patterns of susceptibility of organisms to
the agent being evaluated. Species-specific ECVs have been previ-
ously defined based on MIC data from a single laboratory (12),
which may not completely represent the WTMIC population for
each species ofCandida and each of the three triazoles evaluated in
the present study. Because of this, we used data from multiple
laboratories to define ECVs for fluconazole, posaconazole, and
voriconazole, for the five most prevalent Candida spp., and for C.
dubliniensis, C. guilliermondii, and C. lusitaniae (Tables 1 to 4). In
addition,MIC distributions for another four less prevalent species
are provided (Tables 1 to 3).
Eighteen laboratories submitted MIC data for the present
study. MICs from between 1 and 7 laboratories, depending on the
species and antifungal agent, were not included in the final anal-
ysis due to truncated distributions (modal MIC at the lowest con-
centration tested). All of the MIC distributions were typical for
WT organisms and covered 3 to 5 2-fold dilution steps surround-
ing the modal MIC. The remaining aggregated MIC distributions
for the three triazoles that originated in 3 to 15 laboratories are
TABLE 2 Pooled MIC distributions of posaconazole for 12 Candida species
Species
No. of
labsa
No. of
isolates
No. of isolates for which the MIC (g/ml)wasb:
0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 8
C. albicans 9c 11,241 976 5,197 3,365 1,230 259 132 55 13 3 1 10
C. dubliniensis 7 151 2 14 51 38 35 8 3
C. glabrata 7 2,131 7 59 127 193 386 602 520 153 46 18 20
C. guilliermondii 6 298 1 9 28 38 115 79 22 4 2
C. krusei 10 872 5 37 109 253 356 87 20 3 2
C. lusitaniae 7c 521 8 199 167 97 37 8 2 3
C. parapsilosis 7c 3,451 43 446 1,033 1,024 678 165 45 13 4
C. tropicalis 8 2,613 103 661 860 646 249 50 20 6 6 4 8
C. famata 6 45 4 11 20 7 2 1
C. kefyr 6 29 2 9 11 4 3
C. orthopsilosis 3 55 1 8 24 15 7
C. rugosa 8 45 4 11 20 7 2 1
a Number of laboratories contributing data to each MIC distribution.
b MICs determined at 24 h as described in the CLSI M27-A3 reference method (17). The modal MIC (most frequent value) for each distribution is underlined.
c Data from the other 2 to 4 labs were not used due to abnormal MIC distributions (the mode and lowest concentration tested were the same).
TABLE 3 Pooled MIC distributions of voriconazole for 12 Candida species
Species
No. of
labsa
No. of
isolates
No. of isolates for which the MIC (g/ml) wasb:
0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 8
C. albicans 9c 3,210 105 1,768 670 291 140 114 84 21 11 2 4
C. dubliniensis 7 152 52 86 7 3 2 1 1
C. glabrata 11 4,176 13 208 556 1,476 983 304 166 162 172 112 24
C. guilliermondii 12 369 3 42 126 119 33 20 12 8 1 3 2
C. krusei 12 930 1 8 36 136 476 207 53 12 1
C. lusitaniae 8c 142 23 61 51 6 1
C. parapsilosis 8c 2,337 188 986 547 334 119 80 46 26 11
C. tropicalis 8c 3,127 547 912 893 441 155 69 43 31 21 8 7
C. famata 9 53 6 10 23 10 3 1
C. kefyr 7 34 4 17 11 1 1
C. orthopsilosis 4 66 9 30 17 9 1
C. rugosa 9 59 1 6 34 12 3 3
a Number of laboratories contributing data to each MIC distribution.
b MICs determined at 24 h as described in the CLSI M27-A3 reference method (17). The modal MIC (most frequent value) for each distribution is underlined.
c Data from 1 to 7 labs were not used due to abnormal MIC distributions (the mode and lowest concentration tested were the same).
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shown in Tables 1 to 3. Overall, the distributions were quite nor-
mal; similar-sized “bars” were observed with some of the agent
and species combinations (e.g., at fluconazole MICs of 0.12 and
0.25g/ml for C. albicans and 0.12 and 0.25g/ml for C. dublini-
ensis), which indicated that the mode lies between those two con-
centrations. The fluconazole modal MICs ranged from 0.12 to 16
g/ml; the lower value was for C. albicans, and the highest was for
C. krusei (Tables 1 and 4). The lowest posaconazole modes were
for C. albicans and C. lusitaniae (0.016 g/ml), and the highest
were for C. glabrata and C. krusei (0.25 g/ml). Overall, the vori-
conazole modes were lower (0.016 to 0.03 g/ml) than those of
the other two azoles for most of the species, with the exception of
C. glabrata and C. krusei (voriconazole modes, 0.06 and 0.12 g/
ml, respectively). Our MIC distributions are similar to those ob-
served by other authors (33–37). Previously reported azole MICs
for C. dubliniensis (fluconazole MIC90 range, 8 to 32 g/ml) and
C. guilliermondii (fluconazole MIC90 range, 16 to 32 g/ml; vori-
conazole MIC90 range, 4 to 8 g/ml) were higher than those ob-
served in the present study (Tables 1 to 3).
The triazole ECVs based on the aggregated MIC distributions
of 8 of the 12 Candida spp. evaluated are shown in Table 4. Al-
though the MIC distributions are provided for four less prevalent
species (C. famata, C. kefyr, C. orthopsilosis, and C. rugosa), their
ECVs were not calculated because the current criterion for ECV
definition requires that the total pooled distribution have 100
isolates from 3 laboratories. The ECVs were defined using
95%,97.5%, and99% of themodeledMIC populations; we
focused on themore conservative values (lower ECVs encompass-
ing95% of the modeled population). This decision was corrob-
orated by the genetic information discussed below for the four
more prevalent species and C. dubliniensis, although the ECVs
encompassing 97% of the population were similar to those at
95%. ECVs defined using CLSIMIC data from a single laboratory
are the same or 1 to 2 dilutions higher than those in the present
study (12); in contrast, ECVs using YeastOneMIC data aremostly
higher (38). The European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) has cutoff values for Candida and the
azoles, and it has established ECVs (ECOFFs) for fluconazole,
posaconazole, and voriconazole, respectively, of 1, 0.06, and 0.125
g/ml for C. albicans, of 32, 1, and 1g/ml for C. glabrata, of 128,
0.5, and 1g/ml forC. krusei, and of 2, 0.06, and 0.12g/ml forC.
parapsilosis and C. tropicalis (see http://www.EUCAST.org). For
the most part, with the exception of C. glabrata and fluconazole,
these values are comparable to those reported herein.
The ability of the ECVs encompassing 95% of the statistically
modeled population to differentiate strains of Candida spp. with
intrinsic or acquired azole resistance mechanisms (e.g., substitu-
tions and missense mutations in or upregulation of ERG11,
MDR1, CDR1, or CDR2) may be seen in the data presented in
Table 5. The isolates in the collection depicted in Table 5 were
compiled from 13 previously published studies to represent WT
andnon-WTMIC results for fluconazole, posaconazole, and vori-
TABLE 4 Epidemiological cutoff values from 6 to 15 laboratories as determined by the CLSI M27-A3 broth microdilution method
Antifungal agent Species
No. of isolates/no.
of labs MIC (range) (g/ml) Mode (g/ml)a
ECV (g/ml) at
the indicated % of
the modeled WT
populationb
95 97.5
Fluconazole C. albicans 5,265/9 0.06 to128 0.12 0.5 0.5
C. dubliniensis 162/7 0.06 to 64 0.25 0.5 0.5
C. glabrata 7,538/14 0.12 to128 4 8 8
C. guilliermondii 373/11 0.12 to 64 2 8 8
C. krusei 1,073/11 0.25 to128 16 32 32
C. lusitaniae 574/10 0.12 to 64 0.5 1 1
C. parapsilosis 6,023/15 0.06 to128 0.5 1 1
C. tropicalis 3,748/14 0.06 to128 0.25 1 1
Posaconazole C. albicans 11,241/9 0.008 to8 0.016 0.06 0.06
C. dubliniensis 151/7 0.008 to 0.5 0.03 0.25 0.25
C. glabrata 2,131/7 0.008 to8 0.25 1 2
C. guilliermondii 298/6 0.008 to 2 0.12 0.5 0.5
C. krusei 872/10 0.016 to 4 0.25 0.5 0.5
C. lusitaniae 521/7 0.008 to 1 0.016 0.06 0.06
C. parapsilosis 3,451/7 0.008 to 2 0.03 0.25 0.25
C. tropicalis 2,613/8 0.008 to8 0.03 0.12 0.12
Voriconazole C. albicans 3,210/9 0.008 to8 0.016 0.03 0.03
C. dubliniensis 152/7 0.008 to 1 0.016 0.03 0.03
C. glabrata 4,176/11 0.008 to8 0.06 0.25 0.25
C. guilliermondii 369/12 0.008 to8 0.03 0.12 0.12
C. krusei 930/12 0.008 to 2 0.12 0.25 0.5
C. lusitaniae 142/8 0.008 to 0.25 0.016 0.06 0.06
C. parapsilosis 2,337/8 0.008 to 2 0.016 0.03 0.03
C. tropicalis 3,127/8 0.008 to8 0.016 0.06 0.12
a Most frequent MIC.
b Calculated ECVs comprising95% or97.5% of the statistically modeled population using pooled MICs originating from 6 to 15 laboratories.
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conazole, and all the isolates were characterized regarding the
presence (non-WT) or absence (WT) of azole resistance mecha-
nisms (6–8, 10, 18–26). A total of 136 isolates harbored molecu-
larly defined azole resistance mechanisms: 47 C. albicans, 26 C.
dubliniensis, and 57 C. glabrata isolates and 3 isolates each of C.
parapsilosis and C. tropicalis (Table 5). The ECVs for fluconazole
and C. albicans, C. dubliniensis, C. glabrata, C. parapsilosis, and C.
tropicalis were 0.5 g/ml, 0.5 g/ml, 8 g/ml, 1 g/ml, and 1
g/ml, respectively (Table 4). Using these fluconazole cutoffs, the
CLSImethod correctly classified all (100%) of the 136 strains with
resistance mutations/mechanisms as non-WT (MIC ECV) and
61 (95.3%) of the 64 strains with no demonstrated resistance mu-
tations/mechanisms as WT strains. The ECVs for posaconazole
and C. albicans, C. dubliniensis, and C. parapsilosis were 0.06 g/
ml, 0.25 g/ml, and 0.25 g/ml, respectively (Table 4). Using
these ECVs, the CLSI method with posaconazole correctly classi-
fied 46 (86.8%) of 53 strains with resistance mutations/mecha-
nisms as non-WT and all 20 (100.0%)WT strains (MIC ECV).
Although a total of 7 isolates (5 of C. albicans and 2 of C. dublini-
ensis) with molecularly defined resistance mechanisms were clas-
sified as WT for posaconazole, this may be explained by the fact
that certain azole resistance mechanisms (e.g., substitutions and
missense mutations in or upregulation of ERG11 or MDR1) may
affect fluconazole to a greater extent than other azoles (6, 18, 19);
all 7 of these isolates were non-WT for fluconazole. The ECVs for
voriconazole and C. albicans, C. dubliniensis, and C. parapsilosis
were all 0.03g/ml, and those forC. glabrata andC. tropicaliswere
0.25 g/ml and 0.06 g/ml, respectively (Table 4). Using these
ECVs, theCLSImethodwhenused for voriconazole correctly clas-
sified 83 (89.2%) of 93 strains with resistance mutations/mecha-
nisms as non-WT and 32 (97%) of the 33 WT strains. As with
posaconazole, all 10 of the strains with molecularly defined resis-
tance mutations/mechanisms that were classified as WT for vori-
conazole were non-WT for fluconazole, reflecting more flucona-
zole-specific resistance mechanisms. These results support the
ability of the triazole ECVs to differentiate WT strains of Candida
spp. from those harboring clinically important resistance mecha-
nisms; additional data for C. parapsilosis and C. tropicalis are
needed.
ECVs forC. krusei and the less prevalent speciesC. guilliermon-
dii and C. lusitaniae are also depicted in Table 4. Since MIC dis-
tributions encompassed less than 100 values, ECVs were not de-
fined for the other four less prevalent species (C. famata, C. kefyr,
C. orthopsilosis, and C. rugosa), but their MIC distributions (Ta-
bles 1 to 3) are provided so that they may serve as a reference for
other studies using the CLSImethod. As expected, the fluconazole
ECV for C. krusei was higher (32 g/ml) than those for C. lusita-
niae and C. guilliermondii (1 and 8 g/ml, respectively). ECVs for
C. guilliermondii, C. krusei, and C. lusitaniae and the other two
triazoles were 0.5, 0.5, and 0.06 g/ml (for posaconazole) and
0.12, 0.25, and 0.06,g/ml (for voriconazole), respectively. To our
knowledge, information regarding mechanisms of resistance is
only available for C. krusei, and resistance to fluconazole has been
postulated to be due to either a decreased sensitivity of the target
enzyme or targetmutations of the efflux pumps (11, 39, 40).More
recently, only a 2-fold decrease in the fluconazole MIC (32 to 8
g/ml) was observed in 1 of the 21 isolates evaluated (fluconazole
MICs  16 g/ml) by using the efflux pump inhibitor carbonyl
cyanide 3-chloro-phenylhydrazone; no changes were observed
among the voriconazole MICs (range, 0.06 to 0.25 g/ml) (37),
and hence the results are inconclusive regarding the efflux pumps.
Due to the innate resistance of C. krusei to fluconazole, the CLSI
does not recommend the interpretation of MICs for this species
and agent (13), a recommendation that should be extended to the
ECV. The CLSI and EUCAST susceptibility BP for C. krusei and
voriconazole is 0.5 g/ml (versus our ECV of 0.25 g/ml); the
EUCAST posaconazole ECV for C. guilliermondii is 0.25 g/ml
(versus our ECV of 0.5 g/ml) (Table 4) (13, 29, 41).
In conclusion, we have defined ECVs for 8 of the 12 Candida
spp. evaluated and the three triazoles (fluconazole ECVs ranged
from 0.5 g/ml for C. albicans and C. dubliniensis to 32 g/ml for
C. krusei, posaconazole ECVs ranged from 0.06 g/ml for C. albi-
cans andC. lusitaniae to 1g/ml forC. glabrata, and voriconazole
ECVs ranged from 0.03 g/ml for C. albicans, C. dubliniensis, and
C. parapsilosis to 0.25 g/ml for C. glabrata and C. krusei). These
ECVs encompass 95% of the statistically modeled population and
will serve to differentiateWT fromnon-WT strains ofCandida for
the three systemically active triazoles. We have demonstrated the
ability of the species-specific ECVs for all three triazoles to identify
those strains of Candida spp. harboring azole resistance mecha-
nisms in a population of 200 well-characterized Candida species.
The ECVs for fluconazole, posaconazole, and voriconazole and
the CLSI broth microdilution method will help in monitoring the
emergence of azole resistance among target species of Candida.
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The findings and conclusions of this article are those of the authors
TABLE 5 Application of ECVs to MIC distributions of fluconazole,
posaconazole, and voriconazole versus Candida species strains tested for
the presence of azole resistance mutations by broth microdilution
methodsa
Species
Antifungal agent
(no. of isolates
tested)
ECV
(g/ml)
No. of isolates by
ECV category (no.
with acquired
resistance
mutation[s])
ECV ECV
C. albicans Fluconazole (65) 0.5 18 47 (47)
Posaconazole (65) 0.06 18 (5) 42 (42)
Voriconazole (65) 0.03 18 (3) 44 (44)
C. dubliniensis Fluconazole (38) 0.5 12 26 (26)
Posaconazole (4) 0.25 1 (2) 1 (1)
Voriconazole (4) 0.03 4 (3)
C. glabrata Fluconazole (89) 8 29 60 (57)
Voriconazole (49) 0.25 12 (7) 30 (30)
C. parapsilosis Fluconazole (4) 1 1 3 (3)
Posaconazole (4) 0.25 1 3 (3)
Voriconazole (4) 0.03 1 3 (3)
C. tropicalis Fluconazole (4) 1 1 3 (3)
Voriconazole (4) 0.06 1 3 (3)
a Data were compiled from references 6–8, 10, and 18–26. Azole resistance mechanisms
included mutations in and overexpression of ERG11 and/or overexpression of MDR or
CDR efflux pumps.
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